Citigroup Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on IDEAYA Biosciences but lowers the price target from $60 to $58.
August 27, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup's analyst Yigal Nochomovitz continues to recommend buying IDEAYA Biosciences stock, but has slightly reduced the price target from $60 to $58, indicating a minor adjustment in expected valuation.
The Buy rating suggests continued confidence in IDEAYA's potential, but the lowered price target indicates a slight reduction in expected upside. This could lead to a neutral short-term impact as the overall sentiment remains positive but with tempered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100